Boston Scientific (NYSE:BSX) Updates Q1 2025 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its first quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.660-0.680 for the period, compared to the consensus earnings per share estimate of 0.650. The company issued revenue guidance of $4.5 billion-$4.6 billion, compared to the consensus revenue estimate of $4.5 billion. Boston Scientific also updated its FY 2025 guidance to 2.800-2.870 EPS.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Truist Financial increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. StockNews.com raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, January 29th. BTIG Research raised their price objective on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, Raymond James lifted their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and a consensus target price of $104.26.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $0.04 during midday trading on Thursday, hitting $105.01. 6,241,721 shares of the company’s stock were exchanged, compared to its average volume of 6,229,090. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The stock’s 50 day moving average price is $94.30 and its 200-day moving average price is $86.84. The firm has a market cap of $154.76 billion, a P/E ratio of 86.78, a PEG ratio of 2.68 and a beta of 0.80. Boston Scientific has a twelve month low of $64.39 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. Equities research analysts anticipate that Boston Scientific will post 2.46 EPS for the current year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,302 shares of company stock valued at $4,464,725 over the last quarter. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.